According to the Tissue Cancer Genome Atlas (TCGA) available datasets, ERK1 is amplified in 16% of ovarian cancers, 9% of bladder cancers, and 6% of lung and breast cancers, with lower percentages in the other cancer types. Here, MAPK3 is linked to breast carcinoma.